A pharmaceutical company in Slough is playing a leading role in the treatment of a devastating muscle disease.

The company Ipsen which has a major centre in Bath Road is a major producer of the protein Dysport.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has now granted a licence update for Dysport in the treatment of focal spasticity, a dysfunction of the central nervous system which is characterized by muscles overactivity, high tone spasms and may lead to muscle and soft tissue contracture and limb deformity

The update to the licence means that any appropriately trained and qualified health care professionals, which now includes physiotherapists, will be able to administer Dysport.

Asad Mohsin Ali, UK & Ireland General Manager for Ipsen said “We welcome this news not only for physiotherapists and their teams across the UK, but also for adult and paediatric spasticity patients who will benefit from having an additional set of health care professionals being able to administer our medicine.

"We are very proud of the fact that Dysport® (which was originally co‐developed with the UK Government) is leading the way on new standards of care in spasticity services to support patients.”